Urogenit Tract Infect.  2015 Oct;10(2):120-125. 10.14777/uti.2015.10.2.120.

Characteristics of Patients Who Visited the Emergency Room after Prostate Biopsy: Single Center Retrospective Study

• Jeong SC
• Lee S
• Chung JM
• Lee SD

• KMID: 2319437
• DOI: http://doi.org/10.14777/uti.2015.10.2.120

Abstract

PURPOSE
To educate patients and prevent biopsy-related complications, it is helpful to understand the causes for visiting the emergency room (ER). Therefore, we want to analyze the causes and factors of complications that cause patients to visit the ER after prostate biopsy.
MATERIALS AND METHODS
We conducted a study of in-patients who visited the ER of Pusan National University Yangsan Hospital after prostate biopsy from December 2008 to July 2015. Age, postoperative interval before visiting the ER, Charlson comorbidity index (CCI) score, symptoms in ER, prostate size, pathologic result, and number of biopsy cores were analyzed retrospectively.
RESULTS
Among all 1,694 cases of patients who had undergone prostate biopsies during a 7-year period, only 37 patients (2.2%) visited the ER. Diabetes mellitus (DM) is the most common underlying disease among patients with accompanying infection-related symptoms compared to patients with accompanying non-infection-related symptoms (p<0.001). In univariate analysis, DM (p=0.004) and CCI score (p=0.030) were statistically significant risk factors for infection, but only DM was significant in multivariate analysis (p=0.004). Prostate size (p=0.044) was a significant risk factor for acute urinary retention (AUR) in univariate analysis, but not statistically significant in multivariate analysis. CCI score was a statistically significant risk factor for bleeding (p=0.005 [univariate], 0.035 [multivariate]).
CONCLUSIONS
AUR after transrectal ultrasound-biopsy is the most common reason for visiting the ER. CCI score showed correlation with bleeding and DM showed correlation with infection. Consideration of risk factors of complications after prostate biopsy will be helpful to the patients in the treatment and prevention of complication.

Keyword

Infection; Diabetes mellitus; Comorbidity; Biopsy; Prostate

MeSH Terms

Biopsy*
Busan
Comorbidity
Diabetes Mellitus
Emergencies*
Emergency Service, Hospital*
Gyeongsangnam-do
Hemorrhage
Humans
Multivariate Analysis
Prostate*
Retrospective Studies*
Risk Factors
Urinary Retention

Reference

1.Rosario DJ., Lane JA., Metcalfe C., Donovan JL., Doble A., Goodwin L, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ. 2012. 344:d7894.

2.Quan H., Sundararajan V., Halfon P., Fong A., Burnand B., Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005. 43:1130–9.

3.Carlsson SV., Holmberg E., Moss SM., Roobol MJ., Schröder FH., Tammela TL, et al. No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. BJU Int. 2011. 107:1912–7.

4.Wei TC., Lin TP., Chang YH., Chen TJ., Lin AT., Chen KK. Transrectal ultrasound-guided prostate biopsy in Taiwan: a nationwide database study. J Chin Med Assoc. 2015. 78:662–5.

5.Pinsky PF., Parnes HL., Andriole G. Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial. BJU Int. 2014. 113:254–9.

6.Loeb S., Carter HB., Berndt SI., Ricker W., Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011. 186:1830–4.

7.Puig J., Darnell A., Bermúdez P., Malet A., Serrate G., Baré M, et al. Transrectal ultrasound-guided prostate biopsy: is antibiotic prophylaxis necessary? Eur Radiol. 2006. 16:939–43.

8.Loeb S., van den Heuvel S., Zhu X., Bangma CH., Schröder FH., Roobol MJ. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol. 2012. 61:1110–4.

9.Batura D., Gopal Rao G. The national burden of infections after prostate biopsy in England and Wales: a wake-up call for better prevention. J Antimicrob Chemother. 2013. 68:247–9.

10.Wagenlehner FM., van Oostrum E., Tenke P., Tandogdu Z., Çek M., Grabe M, et al. GPIU investigators. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol. 2013. 63:521–7.

11.Simsir A., Kismali E., Mammadov R., Gunaydin G., Cal C. Is it possible to predict sepsis, the most serious complication in prostate biopsy? Urol Int. 2010. 84:395–9.

12.de Jesus CM., Corrêa LA., Padovani CR. Complications and risk factors in transrectal ultrasound-guided prostate biopsies. Sao Paulo Med J. 2006. 124:198–202.

13.Zaytoun OM., Vargo EH., Rajan R., Berglund R., Gordon S., Jones JS. Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology. 2011. 77:1035–41.

14.Shigemura K., Matsumoto M., Tanaka K., Yamashita M., Arakawa S., Fujisawa M. Efficacy of combination use of Beta-lactamase inhibitor with penicillin and fluoroquinolones for antibiotic prophylaxis in transrectal prostate biopsy. Korean J Urol. 2011. 52:289–92.

15.Raheem OA., Casey RG., Galvin DJ., Manecksha RP., Varadaraj H., McDermott T, et al. Discontinuation of anticoagulant or antiplatelet therapy for transrectal ultrasound-guided prostate biopsies: a single-center experience. Korean J Urol. 2012. 53:234–9.

16.Nam RK., Saskin R., Lee Y., Liu Y., Law C., Klotz LH, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2013. 189(1 Suppl):S12–7. discussion S17-8.

17.Carignan A., Roussy JF., Lapointe V., Valiquette L., Sabbagh R., Pépin J. Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis? Eur Urol. 2012. 62:453–9.

18.Tal R., Livne PM., Lask DM., Baniel J. Empirical management of urinary tract infections complicating transrectal ultrasound guided prostate biopsy. J Urol. 2003. 169:1762–5.

19.Suzuki M., Kawakami S., Asano T., Masuda H., Saito K., Koga F, et al. Safety of transperineal 14-core systematic prostate biopsy in diabetic men. Int J Urol. 2009. 16:930–5.

20.Jeon SS., Woo SH., Hyun JH., Choi HY., Chai SE. Bisacodyl rectal preparation can decrease infectious complications of transrectal ultrasound-guided prostate biopsy. Urology. 2003. 62:461–6.

21.Utrera NM., Álvarez MB., Polo JM., Sánchez AT., Martínez JP., González RD. Infectious complications after transrectal ultrasound-guided prostatic biopsy. Analysis of our experience. Arch Esp Urol. 2011. 64:605–10.

22.Pal RP., Elmussareh M., Chanawani M., Khan MA. The role of a standardized 36 core template-assisted transperineal prostate biopsy technique in patients with previously negative transrectal ultrasonography-guided prostate biopsies. BJU Int. 2012. 109:367–71.

23.Loeb S., Carter HB., Berndt SI., Ricker W., Schaeffer EM. Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare. J Urol. 2013. 189:867–70.

24.Pinkhasov GI., Lin YK., Palmerola R., Smith P., Mahon F., Kaag MG, et al. Complications following prostate needle biopsy requiring hospital admission or emergency department visits: experience from 1000 consecutive cases. BJU Int. 2012. 110:369–74.

25.Lee SH., Chen SM., Ho CR., Chang PL., Chen CL., Tsui KH. Risk factors associated with transrectal ultrasound guided prostate needle biopsy in patients with prostate cancer. Chang Gung Med J. 2009. 32:623–7.

26.Zaytoun OM., Anil T., Moussa AS., Jianbo L., Fareed K., Jones JS. Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors. Urology. 2011. 77:910–4.

27.de la Taille A., Antiphon P., Salomon L., Cherfan M., Porcher R., Hoznek A, et al. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology. 2003. 61:1181–6.

28.Berger AP., Gozzi C., Steiner H., Frauscher F., Varkarakis J., Rogatsch H, et al. Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. J Urol. 2004. 171:1478–80. discussion 1480-1.

29.Argyropoulos AN., Doumas K., Farmakis A., Liakatas I., Gkialas I., Lykourinas M. Time of administration of a single dose of oral levofloxacin and its effect in infectious complications from transrectal prostate biopsy. Int Urol Nephrol. 2007. 39:897–903.

30.Li H., Yan W., Zhou Y., Ji Z., Chen J. Transperineal ultrasound-guided saturation biopsies using 11-region template of prostate: report of 303 cases. Urology. 2007. 70:1157–61.

31.Raaijmakers R., Kirkels WJ., Roobol MJ., Wildhagen MF., Schrder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology. 2002. 60:826–30.

32.Chiang IN., Chang SJ., Pu YS., Huang KH., Yu HJ., Huang CY. Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: a retrospective study of 1875 cases in taiwan. J Formos Med Assoc. 2007. 106:929–34.